Kevin O’Hayer

726 total citations
18 papers, 568 citations indexed

About

Kevin O’Hayer is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Kevin O’Hayer has authored 18 papers receiving a total of 568 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Kevin O’Hayer's work include Epigenetics and DNA Methylation (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Kevin O’Hayer is often cited by papers focused on Epigenetics and DNA Methylation (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Kevin O’Hayer collaborates with scholars based in United States, Belgium and United Kingdom. Kevin O’Hayer's co-authors include Christopher M. Counter, Channing J. Der, Sara Kendall, Kian‐Huat Lim, Stacey J. Adam, Paul M. Campbell, Jonathan R. Brody, Jordan M. Winter, Saswati N. Chand and Fernando F. Blanco and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Kevin O’Hayer

18 papers receiving 558 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin O’Hayer United States 10 315 263 113 88 75 18 568
Jessica Wagner United States 12 344 1.1× 408 1.6× 213 1.9× 74 0.8× 49 0.7× 24 751
Francis G Gabriel United Kingdom 9 142 0.5× 165 0.6× 99 0.9× 77 0.9× 14 0.2× 11 358
Chongkui Sun China 13 337 1.1× 192 0.7× 125 1.1× 124 1.4× 31 0.4× 16 621
Junfeng Wu China 14 252 0.8× 149 0.6× 190 1.7× 62 0.7× 75 1.0× 26 547
Raluca A. Budiu United States 13 230 0.7× 129 0.5× 249 2.2× 150 1.7× 20 0.3× 14 646
Masahiko Yabu Japan 6 241 0.8× 80 0.3× 162 1.4× 148 1.7× 41 0.5× 6 407
Dilshad H. Khan Canada 12 732 2.3× 163 0.6× 90 0.8× 108 1.2× 26 0.3× 22 887
T. V. Kalinichenko United States 6 386 1.2× 344 1.3× 150 1.3× 88 1.0× 57 0.8× 7 646
Asel Biktasova United States 9 260 0.8× 157 0.6× 166 1.5× 78 0.9× 18 0.2× 10 502
Mariam Markouli Greece 12 286 0.9× 104 0.4× 65 0.6× 95 1.1× 45 0.6× 27 469

Countries citing papers authored by Kevin O’Hayer

Since Specialization
Citations

This map shows the geographic impact of Kevin O’Hayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin O’Hayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin O’Hayer more than expected).

Fields of papers citing papers by Kevin O’Hayer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin O’Hayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin O’Hayer. The network helps show where Kevin O’Hayer may publish in the future.

Co-authorship network of co-authors of Kevin O’Hayer

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin O’Hayer. A scholar is included among the top collaborators of Kevin O’Hayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin O’Hayer. Kevin O’Hayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Luke, Jason J., Marwan Fakih, Charles Schneider, et al.. (2023). Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British Journal of Cancer. 128(12). 2227–2235. 19 indexed citations
2.
Diamond, J.M., Robin Vos, Hilary J. Goldberg, et al.. (2022). Efficacy and Safety of the Janus Kinase 1 Inhibitor Itacitinib (ITA) in Patients with Bronchiolitis Obliterans (BOS) Syndrome Following Double Lung Transplant. The Journal of Heart and Lung Transplantation. 41(4). S113–S113. 1 indexed citations
3.
Rein, Lindsay, Karel Calero, Kristin Hudock, et al.. (2022). Randomized Phase 3 Trial of Ruxolitinib for COVID-19–Associated Acute Respiratory Distress Syndrome*. Critical Care Medicine. 50(12). 1701–1713. 22 indexed citations
4.
Cutsem, Eric Van, Hans Prenen, Kristen Spencer, et al.. (2021). 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. SHILAP Revista de lepidopterología. A559–A560. 11 indexed citations
5.
Piha‐Paul, Sarina A., Tara C. Mitchell, Solmaz Sahebjam, et al.. (2020). 419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial. Regular and Young Investigator Award Abstracts. A255–A255. 3 indexed citations
6.
Nevler, Avinoam, Alexander J. Muller, Erika Sutanto‐Ward, et al.. (2018). Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS -Driven Sporadic Pancreatic Cancers. Clinical Cancer Research. 25(2). 724–734. 41 indexed citations
7.
O’Hayer, C. Virginia, Kevin O’Hayer, & Ashwin R. Sama. (2018). Acceptance and Commitment Therapy with Pancreatic Cancer: An Integrative Model of Palliative Care—A Case Report. SHILAP Revista de lepidopterología. 4(1). 1–3. 6 indexed citations
8.
Zarei, Mahsa, Shruti Lal, Ali Vaziri‐Gohar, et al.. (2018). RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer. Molecular Cancer Research. 17(2). 508–520. 15 indexed citations
9.
Balar, Arjun Vasant, Elizabeth R. Plimack, Petros Grivas, et al.. (2018). Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.. Journal of Clinical Oncology. 36(15_suppl). TPS4587–TPS4587. 8 indexed citations
10.
Chand, Saswati N., Kevin O’Hayer, Fernando F. Blanco, Jordan M. Winter, & Jonathan R. Brody. (2016). The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. International Journal of Biological Sciences. 12(3). 273–282. 89 indexed citations
11.
Cheung, Edwin, Shruti Lal, Mahsa Zarei, et al.. (2016). Abstract 2854: CRISPR knockout of HuR in pancreatic cancer cells causes a xenograft lethal phenotype. Cancer Research. 76(14_Supplement). 2854–2854. 1 indexed citations
12.
O’Hayer, Kevin & Jonathan R. Brody. (2016). Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both?. PubMed. 21(114). 117–23. 8 indexed citations
13.
O’Hayer, Kevin, et al.. (2016). Abstract 394: Novel pan-PIM/pan-PI3K/mTOR inhibitors are highly active in preclinical models of pancreatic ductal adenocarcinoma. Cancer Research. 76(14_Supplement). 394–394. 1 indexed citations
14.
O’Hayer, Kevin, John L. Farber, Charles J. Yeo, & Ashwin R. Sama. (2015). HER-2-Positive Ampullary Adenocarcinoma: A Case Report. PubMed. 1(1). 7–10. 3 indexed citations
15.
O’Hayer, Kevin, Donita C. Brady, & Christopher M. Counter. (2009). ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. Carcinogenesis. 30(11). 1841–1847. 31 indexed citations
16.
O’Hayer, Kevin, et al.. (2008). Oncogenic Ras-Induced Expression of Cytokines: A New Target of Anti-Cancer Therapeutics. Molecular Interventions. 8(1). 22–27. 75 indexed citations
17.
Lim, Kian‐Huat, Kevin O’Hayer, Stacey J. Adam, et al.. (2006). Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells. Current Biology. 16(24). 2385–2394. 195 indexed citations
18.
O’Hayer, Kevin & Christopher M. Counter. (2006). A Genetically Defined Normal Human Somatic Cell System to Study Ras Oncogenesis In Vivo and In Vitro. Methods in enzymology on CD-ROM/Methods in enzymology. 407. 637–647. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jessica Wagner Breakdown of academic impact, for papers by Francis G Gabriel Breakdown of academic impact, for papers by Chongkui Sun Breakdown of academic impact, for papers by Junfeng Wu Breakdown of academic impact, for papers by Raluca A. Budiu Breakdown of academic impact, for papers by Masahiko Yabu Breakdown of academic impact, for papers by Dilshad H. Khan Breakdown of academic impact, for papers by T. V. Kalinichenko Breakdown of academic impact, for papers by Asel Biktasova Breakdown of academic impact, for papers by Mariam Markouli
Rankless by CCL
2026